Comparative Pharmacology
Head-to-head clinical analysis: BENYLIN versus CETIRIZINE HYDROCHLORIDE HIVES RELIEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENYLIN versus CETIRIZINE HYDROCHLORIDE HIVES RELIEF.
BENYLIN vs CETIRIZINE HYDROCHLORIDE HIVES RELIEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BENYLIN (diphenhydramine) is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, thereby alleviating allergic symptoms. It also crosses the blood-brain barrier and acts as a central nervous system depressant via inhibition of histamine and acetylcholine, producing sedative, antiemetic, and antitussive effects.
Selective peripheral H1-receptor antagonist. Competitively inhibits histamine at the H1 receptor, preventing histamine-mediated symptoms such as pruritus, sneezing, and rhinorrhea.
Oral: 10-20 mL (25-50 mg diphenhydramine) every 4-6 hours; maximum 100 mg per day.
Oral, 10 mg once daily; may be increased to 10 mg twice daily if needed.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in adults; extended to 10-12 hours in hepatic impairment, increasing risk of accumulation.
Terminal elimination half-life is approximately 8-11 hours in healthy adults; increases to approximately 20 hours in renal impairment (CrCl <40 mL/min).
Renal: ~80% as unchanged drug and glucuronide conjugates; fecal/biliary: ~20%.
Approximately 70% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion; 10% is excreted in feces. Biliary excretion is minimal.
Category C
Category A/B
Antihistamine
Antihistamine